Karyopharm Therapeutics (KPTI) Corporate presentation summary

Strategic highlights and pipeline progress

• 2026 is positioned as a transformative year with major Phase 3 readouts for selinexor in myelofibrosis and endometrial cancer, targeting multi-billion dollar markets.

• XPOVIO (selinexor) is approved in over 50 countries, with growing global demand and a differentiated mechanism of action.

• Commercial infrastructure in the U.S. is established and can support launches in additional indications.

• Engagement with FDA and global regulators is ongoing, with late-breaking presentations and potential compendia inclusion anticipated.

Myelofibrosis clinical data and commercial opportunity

• Phase 3 SENTRY trial showed selinexor plus ruxolitinib nearly doubled SVR35 rates at week 24 (50% vs. 28%) compared to ruxolitinib alone, with rapid and sustained spleen volume reduction.

• Overall survival signal was promising, with a hazard ratio of 0.43 and >50% reduction in risk of death.

• Variant allele frequency reduction suggests potential disease modification.

• Safety profile was manageable and consistent with known profiles; no new safety signals identified.

• U.S. market opportunity for selinexor plus ruxolitinib could reach ~$1B annually at peak, with a concentrated key account base.

Endometrial cancer clinical data and market potential

• Phase 3 XPORT-EC-042 trial targets TP53 wild-type endometrial cancer, a subgroup with high unmet need and no approved maintenance therapies.

• SIENDO trial subgroup analysis showed selinexor improved median PFS to 28.4 months vs. 5.2 months for placebo (HR 0.44).

• Safety profile in endometrial cancer was consistent with known adverse events, with nausea, vomiting, and thrombocytopenia most common.

• U.S. endometrial cancer maintenance market is estimated at over $2B, with selinexor positioned as the first novel oral maintenance therapy for TP53 wild-type patients.